Evidence map›Paper›PMID 25990368›Full record

ArticleBreast cancer research : BCR2015

Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.

Jie Yuan, Manran Liu, Li Yang, Gang Tu, Qing Zhu, Maoshan Chen, Hong Cheng, Haojun Luo, Weijie Fu, Zhenhua Li and 1 more

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 119 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Anoikis: To Die or Not to Die?International journal of molecular sciences · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jie YuanDepartment of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, #1 You-Yi Rd, Yu-zhong District, Chongqing, 400016, China. yuanjie630805104@163.com.
Manran LiuKey Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing, 400016, China. mliu-hncq@hotmail.com.
Li YangKey Laboratory of Laboratory Medical Diagnostics, Chinese Ministry of Education, Chongqing Medical University, Chongqing, 400016, China. sunny_6103@163.com.
Gang TuDepartment of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, #1 You-Yi Rd, Yu-zhong District, Chongqing, 400016, China. tugang68@126.com.
Qing ZhuDepartment of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, #1 You-Yi Rd, Yu-zhong District, Chongqing, 400016, China. zhuqing198897@163.com.
Maoshan ChenDepartment of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, #1 You-Yi Rd, Yu-zhong District, Chongqing, 400016, China. maoshanchen@126.com.
Hong ChengDepartment of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, #1 You-Yi Rd, Yu-zhong District, Chongqing, 400016, China. eschenghong@126.com.
Haojun LuoDepartment of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, #1 You-Yi Rd, Yu-zhong District, Chongqing, 400016, China. luo_asa@163.com.
Weijie FuDepartment of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, #1 You-Yi Rd, Yu-zhong District, Chongqing, 400016, China. 895916380@qq.com.
Zhenhua LiDepartment of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, #1 You-Yi Rd, Yu-zhong District, Chongqing, 400016, China. Lizhenhua_35@126.com.
Guanglun YangDepartment of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, #1 You-Yi Rd, Yu-zhong District, Chongqing, 400016, China. guanglunyang@163.com.
Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAcquired tamoxifen resistance remains the major obstacle to breast cancer endocrine therapy. β1-integrin was identified as one of the target genes of G protein-coupled estrogen receptor (GPER), a novel estrogen receptor recognized as an initiator of tamoxifen resistance. Here, we investigated the role of β1-integrin in GPER-mediated tamoxifen resistance in breast cancer.

methodsThe expression of β1-integrin and biomarkers of epithelial-mesenchymal transition were evaluated immunohistochemically in 53 specimens of metastases and paired primary tumors. The function of β1-integrin was investigated in tamoxifen-resistant (MCF-7R) subclones, derived from parental MCF-7 cells, and MCF-7R β1-integrin-silenced subclones in MTT and Transwell assays. Involved signaling pathways were identified using specific inhibitors and Western blotting analysis.

resultsGPER, β1-integrin and mesenchymal biomarkers (vimentin and fibronectin) expression in metastases increased compared to the corresponding primary tumors; a close expression pattern of β1-integrin and GPER were in metastases. Increased β1-integrin expression was also confirmed in MCF-7R cells compared with MCF-7 cells. This upregulation of β1-integrin was induced by agonists of GPER and blocked by both antagonist and knockdown of it in MCF-7R cells. Moreover, the epidermal growth factor receptor/extracellular regulated protein kinase (EGFR/ERK) signaling pathway was involved in this transcriptional regulation since specific inhibitors of these kinases also reduced the GPER-induced upregulation of β1-integrin. Interestingly, silencing of β1-integrin partially rescued the sensitivity of MCF-7R cells to tamoxifen and the α5β1-integrin subunit is probably responsible for this phenomenon. Importantly, the cell migration and epithelial-mesenchymal transition induced by cancer-associated fibroblasts, or the product of cancer-associated fibroblasts, fibronectin, were reduced by knockdown of β1-integrin in MCF-7R cells. In addition, the downstream kinases of β1-integrin including focal adhesion kinase, Src and AKT were activated in MCF-7R cells and may be involved in the interaction between cancer cells and cancer-associated fibroblasts.

conclusionsGPER/EGFR/ERK signaling upregulates β1-integrin expression and activates downstream kinases, which contributes to cancer-associated fibroblast-induced cell migration and epithelial-mesenchymal transition, in MCF-7R cells. GPER probably contributes to tamoxifen resistance via interaction with the tumor microenvironment in a β1-integrin-dependent pattern. Thus, β1-integrin may be a potential target to improve anti-hormone therapy responses in breast cancer patients.

Indexed as

Drug Resistance, NeoplasmEpithelial-Mesenchymal TransitionAntineoplastic Agents, HormonalBiomarkersBreast NeoplasmsCell Line, TumorErbB ReceptorsExtracellular Signal-Regulated MAP KinasesFemaleFibroblastsFibronectinsFocal Adhesion Protein-Tyrosine KinasesHumansImmunohistochemistryIntegrin beta1MCF-7 CellsAntineoplastic Agents, HormonalBiomarkersErbB ReceptorsExtracellular Signal-Regulated MAP KinasesFibronectinsFocal Adhesion Protein-Tyrosine KinasesIntegrin beta1Receptors, EstrogenSelective Estrogen Receptor Modulatorssrc-Family KinasesTamoxifen

Identifiers

PMID25990368
PMCPMC4453053
OpenAlexW1922475963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.